Business
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, tod
About this update from 60 Degrees Pharmaceuticals, Inc.
[{"type":"image","alt":"Sixty Degrees Pharmaceuticals","displaySize":"","headline":null,"caption":"Sixty Degrees Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/L1lrb.zKykt_bMbAkYncaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6c5f734cbdeffb0ff816df4f768b5fa6","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosis","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic fatigue","length":120,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":268,"olType":false},{"type":"text","content":"WASHINGTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that infection with Babesia, a parasite that causes the emerging tick-borne illness called babesiosis, was found in 24 percent of a cohort of 50 patients with chronic fatigue in a study conducted by researchers at North Carolina State University, and published in Pathogens.","length":523,"tagName":"p"},{"type":"text","content":"Results announced today contribute to efforts to confirm a long-held theory within the U.S. vector-borne disease community that Babesia and chronic disease may be linked – specifically, that Babesia infection may prolong recovery times in patients with chronic fatigue.","length":269,"tagName":"p"},{"type":"text","content":"The results also reinforce the importance of the B-Free Chronic Babesiosis Study (NCT06656351), which is evaluating efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days for resolution of severe fatigue in patients with chronic babesiosis. The Company’s B-Free Study is now enrolling at the Icahn School of Medicine at Mount Sinai in New York.","length":375,"tagName":"p"},{"type":"text","conten...